[go: up one dir, main page]

CA2542277A1 - Technique de traitement de prevention d'inflammation respiratoire avec un inhibiteur de cyclooxygenase-2 combine a un inhibiteur de phosphodiesterase 4 et compositions a partir deceux-ci - Google Patents

Technique de traitement de prevention d'inflammation respiratoire avec un inhibiteur de cyclooxygenase-2 combine a un inhibiteur de phosphodiesterase 4 et compositions a partir deceux-ci Download PDF

Info

Publication number
CA2542277A1
CA2542277A1 CA002542277A CA2542277A CA2542277A1 CA 2542277 A1 CA2542277 A1 CA 2542277A1 CA 002542277 A CA002542277 A CA 002542277A CA 2542277 A CA2542277 A CA 2542277A CA 2542277 A1 CA2542277 A1 CA 2542277A1
Authority
CA
Canada
Prior art keywords
trifluoromethyl
carboxylic acid
benzopyran
alkyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002542277A
Other languages
English (en)
Inventor
Walter G. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2542277A1 publication Critical patent/CA2542277A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002542277A 2003-10-21 2004-10-21 Technique de traitement de prevention d'inflammation respiratoire avec un inhibiteur de cyclooxygenase-2 combine a un inhibiteur de phosphodiesterase 4 et compositions a partir deceux-ci Abandoned CA2542277A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51309903P 2003-10-21 2003-10-21
US60/513,099 2003-10-21
PCT/US2004/034685 WO2005041864A2 (fr) 2003-10-21 2004-10-21 Technique de traitement de prevention d'inflammation respiratoire avec un inhibiteur de cyclooxygenase-2 combine a un inhibiteur de phosphodiesterase 4 et compositions a partir de ceux-ci

Publications (1)

Publication Number Publication Date
CA2542277A1 true CA2542277A1 (fr) 2005-05-12

Family

ID=34549248

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002542277A Abandoned CA2542277A1 (fr) 2003-10-21 2004-10-21 Technique de traitement de prevention d'inflammation respiratoire avec un inhibiteur de cyclooxygenase-2 combine a un inhibiteur de phosphodiesterase 4 et compositions a partir deceux-ci

Country Status (6)

Country Link
EP (1) EP1691797A2 (fr)
JP (1) JP2007509154A (fr)
BR (1) BRPI0415753A (fr)
CA (1) CA2542277A1 (fr)
MX (1) MXPA06004499A (fr)
WO (1) WO2005041864A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541456B2 (en) 2005-03-08 2013-09-24 Takeda Gmbh Roflumilast for the treatment of diabetes mellitus type 2

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
GB0218868D0 (en) 2002-08-14 2002-09-25 Nasir Muhammed A Improved airway management device
MXPA04008070A (es) 2003-03-10 2004-11-26 Altana Pharma Ag Novedoso proceso para la preparacion de roflumilasto.
CA2535849C (fr) 2003-08-14 2013-03-26 Muhammed Aslam Nasir Dispositif d'intubation ameliore
WO2005107749A1 (fr) * 2004-05-10 2005-11-17 Altana Pharma Ag Utilisation de roflumilast pour la prevention ou le traitement d'un emphyseme
US8663694B2 (en) 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast
JP5908884B2 (ja) * 2010-03-15 2016-04-26 ヴァージニア コモンウェルス ユニヴァーシティＶｉｒｇｉｎｉａ Ｃｏｍｍｏｎｗｅａｌｔｈ Ｕｎｉｖｅｒｓｉｔｙ 気道炎症及び粘液線毛輸送機能異常治療用のエアロゾル化したダプソン
GB201010647D0 (en) 2010-06-24 2010-08-11 Docsinnovent Ltd Stopper device
GB201201438D0 (en) 2012-01-27 2012-03-14 Docsinnovent Ltd Improved stopper device
USD761952S1 (en) 2012-07-27 2016-07-19 Docsinnovent Limited Airway device
WO2013131255A1 (fr) * 2012-03-07 2013-09-12 Scinopharm (Changshu) Pharmaceutical, Ltd. Procédé de preparation de roflumilast
WO2013167582A1 (fr) * 2012-05-09 2013-11-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pharmaceutiques pour prévenir ou traiter une maladie pulmonaire obstructive chronique
WO2014026959A1 (fr) * 2012-08-13 2014-02-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pharmaceutiques pour le traitement de la fibrose cistique
GB2546167B (en) 2013-12-17 2018-02-28 Aslam Nasir Muhammed Intubating Airway Device
USD842456S1 (en) 2015-12-15 2019-03-05 Intersurgical Ag Airway device
USD1051359S1 (en) 2015-06-15 2024-11-12 Intersurgical Ag Airway device
GB201720733D0 (en) 2017-12-13 2018-01-24 Ashkal Development Ltd Airway device
JP1652126S (fr) 2019-01-18 2020-02-03
WO2021113498A1 (fr) * 2019-12-03 2021-06-10 The Usa, As Represented By The Secretary, Department Of Health And Human Services Inhibition de la cyclooxygénase 2 permettant le traitement de l'asthme à saa élevé
WO2021124044A1 (fr) * 2019-12-16 2021-06-24 Themis Medicare Limited Composition pharmaceutique d'inhibiteurs de cyclo-oxygénase - 2
CA3126367A1 (fr) * 2020-03-30 2021-09-30 Pulmonem Inc. Formulations de dapsone et methodes d`utilisation
USD1025348S1 (en) 2020-04-16 2024-04-30 Intersurgical Ag Airway device

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US5994379A (en) * 1998-02-13 1999-11-30 Merck Frosst Canada, Inc. Bisaryl COX-2 inhibiting compounds, compositions and methods of use
BR0008059A (pt) * 1999-12-08 2002-03-26 Pharmacia Corp Composições de valdecoxib
TWI256305B (en) * 2000-08-18 2006-06-11 Pharmacia Corp Oral fast-melt pharmaceutical composition of a cyclooxygenase-2 inhibitor and process for preparing the same
CN100496607C (zh) * 2001-09-19 2009-06-10 尼科梅德有限责任公司 Nsaid与pde-4抑制剂的并用药物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541456B2 (en) 2005-03-08 2013-09-24 Takeda Gmbh Roflumilast for the treatment of diabetes mellitus type 2

Also Published As

Publication number Publication date
EP1691797A2 (fr) 2006-08-23
MXPA06004499A (es) 2006-06-27
JP2007509154A (ja) 2007-04-12
BRPI0415753A (pt) 2006-12-19
WO2005041864A2 (fr) 2005-05-12
WO2005041864A3 (fr) 2006-05-18

Similar Documents

Publication Publication Date Title
US20040204472A1 (en) Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
CA2542277A1 (fr) Technique de traitement de prevention d'inflammation respiratoire avec un inhibiteur de cyclooxygenase-2 combine a un inhibiteur de phosphodiesterase 4 et compositions a partir deceux-ci
CA2474016A1 (fr) Traitement du rhume et de la toux par combinaison d'un inhibiteur selectif de la cyclooxygenase-2 et d'un principe actif contre le rhume et la toux, et compositions renfermant ces substances
CA2472199A1 (fr) Compositions et procedes de traitement comprenant des agonistes gamma du recepteur active du proliferateur du peroxysome et des inhibiteurs selectifs de la cyclooxygenase 2.
US20030212138A1 (en) Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
WO2004093870A1 (fr) Traitement et prevention de troubles otiques
CA2556380A1 (fr) Procedes et compositions pour le traitement ou la prevention de troubles psychiatriques avec des inhibiteurs de cox-2 seuls et en combinaison avec des antidepresseurs
CA2457452A1 (fr) Compositions destinees au traitement et a la prevention de douleurs et d'inflammations a l'aide d'un inhibiteur selectif de cyclooxygenase-2 et d'un sulfate de chondroitine
CA2457453A1 (fr) Compositions assurant le traitement et la prevention de douleurs et d'inflammations a l'aide d'un inhibiteur selectif de cyclooxygenase-2 et de glucosamine
US20040220155A1 (en) Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
US20030207846A1 (en) Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
WO2005009340A2 (fr) Procedes destines au traitement ou a la prevention de troubles respiratoires avec un inhibiteur de cyclooxygenase-2 utilise en combinaison avec un antagoniste de recepteur muscarinique et composition les contenant
WO2005049014A1 (fr) Methodes de traitement ou de prevention de troubles oculaires lies au diabete par des inhibiteurs cox-2 seuls ou en association avec des agents anti-diabete classiques
US20050004224A1 (en) Treatment of Alzheimer's disease with the R(-) isomer of a 2-arylpropionic acid non-steroidal anti-inflammatory drug alone or in combination with a cyclooxygenase-2 selective inhibitor
KR20040063112A (ko) 시클로옥시게나제-2 선택성 억제제 및 글루코사민을이용한 통증 및 염증의 치료 및 예방을 위한 조성물

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead